Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer

[1]  E. Bastiaannet,et al.  Predicting postoperative complications and their impact on quality of life and functional status in older patients with breast cancer , 2022, European Journal of Surgical Oncology.

[2]  E. Bastiaannet,et al.  Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands – A comparison of two national prospective longitudinal multi-centre cohort studies , 2021, European journal of cancer.

[3]  H. Wildiers,et al.  Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). , 2021, The Lancet. Oncology.

[4]  H. Cohen,et al.  Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[6]  E. Bastiaannet,et al.  Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study , 2019, Breast Cancer Research and Treatment.

[7]  M. Groenvold,et al.  Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer , 2019, JNCI cancer spectrum.

[8]  S. Edge,et al.  Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[9]  H. Cohen,et al.  Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance) , 2017, Breast Cancer Research and Treatment.

[10]  E. Smets,et al.  Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. , 2016, European journal of cancer.

[11]  Jason D. Wright,et al.  Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL) , 2016, Breast Cancer Research and Treatment.

[12]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[13]  P. Selby,et al.  The prevalence and outcomes of frailty in older cancer patients: a systematic review. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  David A. Williams,et al.  Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy , 2014, Cancer.

[15]  H. Cohen,et al.  Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Seynaeve,et al.  Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. , 2014, Breast.

[17]  Murielle Mauer,et al.  End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Sally W. Vernon,et al.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review , 2012, Breast Cancer Research and Treatment.

[19]  Lang Li,et al.  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Ravasco,et al.  Validation of the Malnutrition Universal Screening Tool (MUST) in cancer , 2011, British Journal of Nutrition.

[21]  B. Rasmussen,et al.  Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. , 2011, Journal of the National Cancer Institute.

[22]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. V. van Tilburg,et al.  The De Jong Gierveld short scales for emotional and social loneliness: tested on data from 7 countries in the UN generations and gender surveys , 2010, European journal of ageing.

[24]  Douglas P Kiel,et al.  Competing Risk of Death: An Important Consideration in Studies of Older Adults , 2010, Journal of the American Geriatrics Society.

[25]  Timothy L Lash,et al.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Korner,et al.  The Geriatric Depression Scale and the Cornell Scale for Depression in Dementia. A validity study , 2006, Nordic journal of psychiatry.

[27]  Aliza K Fink,et al.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Starkstein,et al.  Syndromic validity of apathy in Alzheimer's disease. , 2001, The American journal of psychiatry.

[29]  T. Lash,et al.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C J Lennings,et al.  Optimism, Satisfaction and Time Perspective in the Elderly , 2000, International journal of aging & human development.

[31]  N. Aaronson,et al.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[33]  Diane Podsiadlo,et al.  The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.

[34]  T. Suurmeijer,et al.  The development of a hierarchical polychotomous ADL-IADL scale for noninstitutionalized elders. , 1990, The Gerontologist.

[35]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[36]  H. Putter,et al.  Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. , 2012, The oncologist.

[37]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[39]  Hadley Cantril,et al.  The pattern of human concerns , 1965 .